GlassScriptPhysician profile
Toni Almeida
NPI 1134523509
$1,738.45
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,634 · 2022: $104.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $295.08 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $246.37 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $212.84 | 2021-2022 | |
| Abbott Laboratories | $167.11 | 2021 | |
| Alnylam Pharmaceuticals INC. | $162.58 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $127.98 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $124.02 | 2021-2022 | |
| Amgen INC. | $121.56 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.27 | 2021 | |
| Sobi, INC | $46.10 | 2021 | |
| Boston Scientific Corporation | $30.64 | 2021 | |
| Pfizer INC. | $22.56 | 2021 | |
| Akcea Therapeutics, INC. | $19.16 | 2021 | |
| Cvrx, INC. | $16.31 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.75 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.10 | 2022 | |
| Vifor Pharma, INC. | $13.02 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toni Almeida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.